Que es el burst release en microsferas?

Liberacion inicial rapida de una fraccion significativa del farmaco (10-50%) en las primeras 24-48 horas. Ocurre por peptido adsorbido en superficie o facilmente accesible. Puede causar efectos adversos por exposicion alta inicial. Se mitiga con optimizacion de formulacion.

Como funciona Atrigel?

Sistema de depot in-situ donde PLGA se disuelve en N-methyl-2-pyrrolidone (NMP). Al inyectarse en tejido acuoso, NMP se difunde y agua entra, precipitando PLGA como gel solido que libera farmaco gradualmente mientras se degrada.

In Vitro-In Vivo Correlation. Relacion predictiva entre perfil de liberacion in vitro y perfil plasmatico in vivo. Permite usar datos in vitro para predecir comportamiento clinico, reducir estudios in vivo, y justificar cambios de manufactura.

Por que Fc fusion extiende vida media?

El dominio Fc de IgG se une al receptor FcRn, que recicla IgG y la protege de degradacion. Esta interaccion da a IgG su vida media de ~21 dias. Fusionar un peptido a Fc le confiere este mecanismo de extension de vida media.

Liberacion Controlada de Peptidos

Categorías: Metodología de Investigación, Información General

Los sistemas de liberacion controlada permiten extender la duracion de accion de peptidos, mejorando compliance y eficacia.

Resumen Simplificado

Microsferas PLGA, implantes, depot inyectables y sistemas basados en carrier prolongan exposicion.

Necesidad de liberacion extendida

Extended release resuelve problemas. Peptide challenges. Short half-life. Minutes to hours. Rapid clearance. Proteolysis. Renal filtration. Frequent dosing. Daily injections. Multiple times daily. Patient burden. Compliance issues. Missed doses. Inconsistent exposure. Peak-trough fluctuations. Efficacy variable. Side effects at peak. Loss of effect at trough. Extended release benefits. Reduced frequency. Weekly to monthly. Improved compliance. Consistent exposure. Steady levels. Better efficacy. Reduced side effects. Smoother profile. Patient convenience. Quality of life. Market differentiation. Competitive advantage. Patent extension. New IP. Extended release transforms therapy. From burden to convenience.

Microsferas PLGA

PLGA microspheres are established. Material. PLGA. Poly(lactic-co-glycolic acid). Biodegradable. Biocompatible. FDA approved. Degradation. Hydrolysis. Lactic and glycolic acids. Metabolized. Mechanism. Encapsulation. Peptide in matrix. Gradual release. Diffusion. Initial burst. Degradation. Bulk erosion. Polymer breakdown. Release kinetics. Affected by. Polymer molecular weight. Lactide:glycolide ratio. Microsphere size. Porosity. Peptide loading. Manufacturing. Emulsion methods. Spray drying. Process control. Critical parameters. Examples. Lupron Depot. Leuprolide. 1-6 months. Sandostatin LAR. Octreotide. Monthly. Trelstar. Triptorelin. Months. Challenges. Burst release. Initial spike. Stability. During encapsulation. Storage. Moisture sensitivity. Scale-up. Complex manufacturing. PLGA microspheres are proven. But technically demanding.

Implantes subcutaneos

Implants provide extended release. Types. Biodegradable. Dissolve over time. No removal needed. Non-biodegradable. Must be removed. Or excreted. Forms. Rods. Cylindrical. Insertion device. Osmotic pumps. Alzet. Research use. Clinical. Tablets. Compressed. Solid forms. Insertion. Minor procedure. Trocar. Pre-filled applicator. Duration. Months. Years in some cases. Examples. Viadur. Leuprolide implant. 1 year. Zoladex. Goserelin. Monthly to 3-month. Implanon. Contraceptive. Not peptide. But similar technology. Advantages. Very long duration. Consistent release. Patient independent. Challenges. Insertion procedure. Removal if needed. Local reactions. Infection risk. Visibility. Patient acceptance. Manufacturing complexity. Implants are longest duration option. For appropriate candidates.

Depot inyectable

Injectable depots are simpler. Mechanisms. Precipitation. Drug forms depot. Slow dissolution. Gel formation. In situ gelling. Temperature-sensitive. pH-sensitive. Viscosity change. Oil solutions. Lipophilic carrier. Slow diffusion. Water-miscible cosolvents. PEG. Propylene glycol. Precipitate on injection. Technologies. In-situ forming depots. Atrigel. PLGA in NMP. Forms gel on contact with water. Oily depots. Vegetable oils. Sesame. Castor. Lipophilic drugs. Microsuspension. Solid particles. Slow dissolution. Examples. Eligard. Leuprolide. In-situ depot. Months. Bydureon. Exenatide. Microspheres. Weekly. Arestin. Minocycline. Local delivery. Advantages. Simple injection. No procedure. Long duration. Challenges. Injection site reactions. Nodules. Pain. Release variability. Initial burst. Depot technology is versatile. Many options available.

Carrier-based systems

Carriers extend half-life. Albumin binding. Fatty acid conjugation. Non-covalent. Reversible. Week-long half-life. Direct albumin fusion. Recombinant. Fc fusion. Antibody Fc domain. IgG half-life. ~21 days. Simple fusion. Proven technology. PEGylation. Covalent PEG attachment. Size increase. Steric shield. Half-life extension. Various sizes. PASylation. PAS polypeptide. Biodegradable. Non-immunogenic. XTEN. Unstructured polypeptide. Hydrophilic. Extended half-life. ELP. Elastin-like polypeptide. Temperature responsive. Depot formation. Liposomes. Lipid vesicles. Encapsulation. Slow release. Targeting possible. Nanoparticles. Various materials. Controlled release. Protection from degradation. Carrier systems are molecular. Not device-based. Often simpler development.

Consideraciones de desarrollo

Development requires planning. Selection criteria. Desired duration. Release profile. Patient population. Route preference. Manufacturing capability. Cost constraints. Stability. Process compatibility. Release kinetics. Design. Target profile. Modelling. In vitro-in vivo correlation. IVIVC. Prediction. Optimization. Manufacturing. Scale-up challenges. Sterility assurance. Process validation. Quality control. Release testing. Content uniformity. Particle size. Sterility. Stability. Real-time. Accelerated. Storage conditions. In-use stability. Regulatory. Extended release guidance. Bioequivalence. Specific studies. Clinical. PK comparison. PD comparison. Efficacy. Safety. Local tolerability. Patient acceptance. Development is comprehensive. Many factors interrelated.

Hallazgos Clave

La liberacion extendida reduce frecuencia de dosificacion y mejora compliance
Las microsferas PLGA liberan por difusion y degradacion del polymero
Los implantes ofrecen la duracion mas larga (meses a anos)
Los depots inyectables usan precipitacion, gelacion o soluciones oleosas
Los carriers (albumin binding, Fc fusion, PEG) extienden vida media molecularmente
El desarrollo requiere IVIVC, estabilidad y consideraciones regulatorias especificas

Más artículos en Metodología de Investigación

Más artículos en Información General

Preguntas frecuentes

Que es el burst release en microsferas?: Liberacion inicial rapida de una fraccion significativa del farmaco (10-50%) en las primeras 24-48 horas. Ocurre por peptido adsorbido en superficie o facilmente accesible. Puede causar efectos adversos por exposicion alta inicial. Se mitiga con optimizacion de formulacion.
Como funciona Atrigel?: Sistema de depot in-situ donde PLGA se disuelve en N-methyl-2-pyrrolidone (NMP). Al inyectarse en tejido acuoso, NMP se difunde y agua entra, precipitando PLGA como gel solido que libera farmaco gradualmente mientras se degrada.
Que es IVIVC?: In Vitro-In Vivo Correlation. Relacion predictiva entre perfil de liberacion in vitro y perfil plasmatico in vivo. Permite usar datos in vitro para predecir comportamiento clinico, reducir estudios in vivo, y justificar cambios de manufactura.
Por que Fc fusion extiende vida media?: El dominio Fc de IgG se une al receptor FcRn, que recicla IgG y la protege de degradacion. Esta interaccion da a IgG su vida media de ~21 dias. Fusionar un peptido a Fc le confiere este mecanismo de extension de vida media.

Volver a la biblioteca de investigación